The Woodlands, TXNCT06241560Now EnrollingIRB Ready

Idiopathic Pulmonary Fibrosis Clinical Trial in The Woodlands, TX

Access cutting-edge idiopathic pulmonary fibrosis treatment through this clinical trial at a research site in The Woodlands. Study-provided care at no cost to qualified participants.

Sponsored by Boehringer Ingelheim

Quick Self-Assessment

See if you qualify for this The Woodlands location

Preparing your pre-screening questions…

Expert Care in The Woodlands

Access idiopathic pulmonary fibrosis specialists at no cost

IRB Approved

This study follows strict safety protocols and ethical guidelines

No-Cost Care

All study-related idiopathic pulmonary fibrosis treatment provided free

Apply for This The Woodlands Location

Check if you qualify for this idiopathic pulmonary fibrosis clinical trial in The Woodlands, TX

Secure & Confidential

Your information is protected and will only be shared with the research team.

Why Participate?

  • No-Cost Study Care

  • Local to The Woodlands

    Convenient for TX residents

  • Cutting-Edge Treatment

    Access to innovative therapies

  • Expert Medical Care

    Close monitoring by specialists

  • Possible Compensation*

    For time and travel

*Compensation varies by study. Confirm details with coordinator.

Simple Process

  1. 1Submit this form
  2. 2Phone screening
  3. 3Visit The Woodlands site if eligible
  4. 4Begin participation

About This Idiopathic Pulmonary Fibrosis Study in The Woodlands

This study is open to adults with idiopathic pulmonary fibrosis (IPF) who are 40 years and older. The purpose of this study is to find out whether a medicine called pirfenidone changes the amount of a medicine called BI 1015550 in the blood. Some people may take more than one medicine at a time. Therefore, it is important to understand how different medicines influence one another. Participants take one dose of BI 1015550 as a tablet. Participants then take one tablet of pirfenidone 3 times a day for one week. The dose is then increased to 2 tablets 3 times a day for the second week. In the third week the dose is increased further to 3 tablets 3 times a day. Participants then take another dose of BI 1015550 as a tablet. Participants are in the study for a little over 1 month. During this time, they visit the study site 15 times. Two of the visits include overnight stays at the study site. The study staff also contacts the participants by phone. During the visits, the doctors collect information about participants' health and take blood samples from the participants. They compare the amount of pirfenidone and BI 1015550 in the blood. Doctors also regularly check participants' health and take note of any unwanted effects.

Sponsor: Boehringer Ingelheim

Who Can Participate

Inclusion Criteria

Male or female patients aged ≥40 years old at the time of signed consent
Patients with idiopathic pulmonary fibrosis (IPF) and an indication/no contraindication for treatment with pirfenidone based on investigator's judgement.
Body mass index (BMI) of 18.5 to 29.9 kg/m\^2 (inclusive)
Signed and dated written informed consent in accordance with International Conference of Harmonization-Good Clinical Practice (ICH-GCP) and local legislation prior to admission to the trial
Women of childbearing potential (WOCBP) must be ready and able to use highly effective methods of birth control. WOCBP taking oral contraceptives (OC) also have to use one barrier method

Exclusion Criteria

Patients with a significant disease or condition other than IPF, which in the opinion of the investigator, may put the patient at risk because of participation, interfere with study procedures, or cause concern regarding the patient's ability to participate in the study
Acute IPF exacerbation within 1 month prior to Visit 1 and/or during the screening period (investigator-determined).
Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2.5 x ULN or total Bilirubin \>1.5 x upper limit of normal (ULN) at Visit 1
Patients with underlying liver cirrhosis (Child Pugh C hepatic impairment)
Cardiovascular diseases, any of the following:
Severe hypertension (uncontrolled under treatment ≥160/100 mmHg at multiple occasions) within 3 months of Visit 1
Myocardial infarction, stroke or transient ischemic attack within 6 months of Visit 1
Unstable cardiac angina within 6 months of Visit 1
Chronic kidney disease with estimated glomerular filtration rate (eGFR) less than 90 ml/min/1.73 m\^2 at Visit 1/screening (Chronic Kidney Disease Epidemiology Collaboration \[CKD-EPI\] formula or Japanese version of CKD-EPI for Japanese patients)
Cholecystectomy or other surgery of the gastrointestinal tract that could interfere with the pharmacokinetics of the trial medication (except appendectomy or simple hernia repair)
Relevant chronic or acute infections including but not limited to human immunodeficiency virus (HIV) and viral hepatitis
Further exclusion criteria apply

Not sure if you qualify? Submit your interest and a study coordinator will help determine your eligibility.

Frequently Asked Questions

Q:Is this study available in The Woodlands?

Yes, this clinical trial (NCT06241560) has an active research site in The Woodlands, TX that is currently enrolling participants.

Q:Is it safe to participate?

Clinical trials follow strict safety guidelines and ethical standards. This study has been reviewed and approved, and participants are closely monitored by medical professionals. You can withdraw at any time.

Q:Will I be compensated?

Many clinical trials offer compensation for your time and travel expenses. Specific compensation details will be discussed during the screening process. All study-related medical care is provided at no cost.

Q:Can I leave the trial if I change my mind?

Absolutely. Participation is completely voluntary. You have the right to withdraw from the study at any time, for any reason, without penalty.

Still have questions? Our study coordinators are here to help.

Idiopathic Pulmonary Fibrosis Treatment Options in The Woodlands, TX

If you're searching for idiopathic pulmonary fibrosis treatment options in The Woodlands, TX, this clinical trial (NCT06241560) may be an excellent opportunity. Clinical trials provide access to cutting-edge treatments that aren't yet available to the general public, often at no cost to participants.

Our The Woodlands research site is actively enrolling participants for this clinical trial. You'll receive care from experienced idiopathic pulmonary fibrosis specialists who are at the forefront of medical research. All study-related care, including examinations, treatments, and monitoring, is provided at no cost to qualified participants.

Looking for more options? Browse all idiopathic pulmonary fibrosis clinical trials near you to find additional studies recruiting in your area.

More Pulmonary Fibrosis Trials in The Woodlands, TX

See all pulmonary fibrosis clinical trials recruiting in The Woodlands — not just this study.

Browse Pulmonary Fibrosis Trials in The Woodlands

Ready to Join in The Woodlands?

Take the first step toward participating in this groundbreaking clinical trial

Secure · Expert Care · The Woodlands, TX